Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic treatment for detrusor overactivity.

H Henry Lai1, Timothy B Boone, Rodney A Appell

  • 1Scott Department of Urology, Baylor College of Medicine, 6560 Fannin Street, Suite 2100, Houston, TX 77030, USA.

Current Urology Reports
|October 2, 2002
PubMed
Summary

Newer antimuscarinic agents offer improved bladder selectivity and drug delivery systems, leading to better side effect profiles for treating overactive bladder. These advancements enhance patient compliance and long-term outcomes compared to older medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Symptoms and subtypes of patients with lower urinary tract dysfunction - insights from the Symptoms of Lower Urinary Tract Dysfunction Research Network.

Nature reviews. Urology·2026
Same author

Generalized Sensory Sensitivity in Patients With Urinary Urgency-A LURN II Urinary Urgency Phenotyping Study.

The Journal of urology·2026
Same author

The LURN Study-What Have We "LURN"ed So Far?

Neurourology and urodynamics·2026
Same author

Lessons learned from conducting a multi-center lower urinary tract physiology study: the LURN experience.

Continence (Amsterdam, Netherlands)·2026
Same author

Reply by Authors.

The Journal of urology·2026
Same author

Prevention of urinary stones with hydration: a randomised clinical trial of an adherence intervention.

Lancet (London, England)·2026

Area of Science:

  • Pharmacology
  • Urology

Background:

  • Detrusor overactivity (DO) is a condition characterized by involuntary bladder contractions.
  • Pharmacologic treatments aim to manage DO symptoms and improve quality of life.

Purpose of the Study:

  • To evaluate recent advancements in pharmacologic treatments for detrusor overactivity.
  • To compare the efficacy and side effect profiles of newer antimuscarinic agents with older treatments.

Main Methods:

  • Review of recent pharmacologic treatments for detrusor overactivity.
  • Analysis of drug delivery systems and bladder selectivity of antimuscarinic agents.
  • Comparison of patient compliance and long-term results.

Main Results:

  • Newer antimuscarinic agents demonstrate improved bladder selectivity.

Related Experiment Videos

  • Advanced drug delivery systems contribute to favorable side effect profiles.
  • Novel agents show higher patient compliance and better long-term results than generic immediate-release oxybutynin.

    • Conclusions:

    • Recent pharmacologic developments have significantly improved treatment outcomes for detrusor overactivity.
    • Improved side effect profiles and enhanced bladder selectivity of newer agents are key factors in better patient compliance and long-term efficacy.